Literature DB >> 16095471

A randomized comparison of group cognitive-behavioural therapy and group psychoeducation in acute patients with schizophrenia: outcome at 24 months.

A Bechdolf1, D Köhn, B Knost, R Pukrop, J Klosterkötter.   

Abstract

OBJECTIVE: We compared the effects of a brief group cognitive-behavioural therapy (CBT) and a group psychoeducational (PE) programme in acute patients with schizophrenia 2 years after treatment. At 6-month follow-up, the CBT group had shown significantly less re-hospitalization rates and on a descriptive level higher compliance with medication.
METHOD: Eighty-eight in-patients with acute schizophrenia were randomized to receive a therapy envelope of 8 weeks including either 16 sessions of CBT or eight sessions of PE.
RESULTS: From the initial sample, 43 patients (48.9%) completed the 24-month follow-up. There were no significant group differences regarding re-admission, symptoms or compliance with medication. However, on a descriptive level patients who received CBT on average experienced 21.8% less re-hospitalizations, 71 days less in hospital and higher compliance ratings at the 24-month follow-up.
CONCLUSION: The significant advantages of CBT at short-term follow-up were lost at long-term follow-up. However, on a descriptive level some advantages for CBT remained after 2 years. Copyright (c) 2005 Blackwell Munksgaard

Entities:  

Mesh:

Year:  2005        PMID: 16095471     DOI: 10.1111/j.1600-0447.2005.00581.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  16 in total

Review 1.  Elderly patients with schizophrenia and depression: diagnosis and treatment.

Authors:  Kandi Felmet; Sidney Zisook; John W Kasckow
Journal:  Clin Schizophr Relat Psychoses       Date:  2011-01

Review 2.  Psychoeducation for schizophrenia.

Authors:  Jun Xia; Lars Bertil Merinder; Madhvi R Belgamwar
Journal:  Cochrane Database Syst Rev       Date:  2011-06-15

Review 3.  Research in people with psychosis risk syndrome: a review of the current evidence and future directions.

Authors:  Christoph U Correll; Marta Hauser; Andrea M Auther; Barbara A Cornblatt
Journal:  J Child Psychol Psychiatry       Date:  2010-02-26       Impact factor: 8.982

4.  Early detection of schizophrenia: current evidence and future perspectives.

Authors:  Heinz Häfner; Kurt Maurer
Journal:  World Psychiatry       Date:  2006-10       Impact factor: 49.548

Review 5.  Defining and assessing adherence to oral antipsychotics: a review of the literature.

Authors:  Dawn I Velligan; Yui-Wing Francis Lam; David C Glahn; Jennifer A Barrett; Natalie J Maples; Larry Ereshefsky; Alexander L Miller
Journal:  Schizophr Bull       Date:  2006-05-17       Impact factor: 9.306

Review 6.  Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia.

Authors:  Christopher Jones; David Hacker; Irene Cormac; Alan Meaden; Claire B Irving
Journal:  Cochrane Database Syst Rev       Date:  2012-04-18

Review 7.  Cognitive behavioural therapy (group) for schizophrenia.

Authors:  Giuseppe Guaiana; Massimiliano Abbatecola; Ghazaleh Aali; Federica Tarantino; Ikenna D Ebuenyi; Valeria Lucarini; Wei Li; Caidi Zhang; Antonio Pinto
Journal:  Cochrane Database Syst Rev       Date:  2022-07-12

Review 8.  Psychoeducation: a basic psychotherapeutic intervention for patients with schizophrenia and their families.

Authors:  Josef Bäuml; Teresa Froböse; Sibylle Kraemer; Michael Rentrop; Gabriele Pitschel-Walz
Journal:  Schizophr Bull       Date:  2006-08-18       Impact factor: 9.306

9.  Costs of an intervention for primary care patients with medically unexplained symptoms: a randomized controlled trial.

Authors:  Zhehui Luo; John Goddeeris; Joseph C Gardiner; Robert C Smith
Journal:  Psychiatr Serv       Date:  2007-08       Impact factor: 3.084

Review 10.  Psychosocial treatments for negative symptoms in schizophrenia: current practices and future directions.

Authors:  Ori Elis; Janelle M Caponigro; Ann M Kring
Journal:  Clin Psychol Rev       Date:  2013-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.